Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.3 (
collagenase
)
18,340
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Matrix metalloproteinases (MMPs) play a role in collagen breakdown, leading to plaque instability. High levels of MMPs mRNA and proteins, especially
MMP-1
, MMP-2,
MMP-8
, MMP-9, and MMP-13, were shown in human atherosclerotic plaques. However, among various MMPs, only
MMP-1
,
MMP-8
and MMP-13, so-called interstitial collagenases, can initiate collagen breakdown. To elucidate whether
MMP-1
,
MMP-8
and MMP-13 levels in blood were high in patients with unstable angina (
UAP
), we measured serum
MMP-1
and plasma
MMP-8
and MMP-13 levels in 45 patients with
UAP
, 175 with stable coronary artery disease (CAD), and 45 controls. Plasma C-reactive protein levels tended to be higher in patients with
UAP
than in those with stable CAD and controls (median 0.94 vs. 0.69 and 0.51mg/l). Regarding blood levels of MMPs, MMP-13 levels were above the lower detection limit in only one patient with
UAP
(2%), one with stable CAD (1%), and none in controls.
MMP-1
levels did not differ among patients with
UAP
, stable CAD, and controls (median 4.8, 5.3, and 5.4ng/ml). Notably,
MMP-8
levels were higher in patients with stable CAD than in controls (median 3.5ng/ml vs. 2.8ng/ml, P<0.005), however,
MMP-8
levels in patients with
UAP
were much higher than those in stable CAD (3.9ng/ml vs. 3.5ng/ml, P<0.05). In multivariate analysis,
MMP-8
level was an independent factor for
UAP
. Thus, plasma
MMP-8
levels were found to be high in patients with
UAP
, suggesting that
MMP-8
levels in
UAP
may reflect coronary plaque instability and that
MMP-8
is a promising biomarker for
UAP
.
...
PMID:High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. 1967 46